These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 22172779)

  • 1. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome.
    Kosmala W; Przewlocka-Kosmala M; Szczepanik-Osadnik H; Mysiak A; O'Moore-Sullivan T; Marwick TH
    JACC Cardiovasc Imaging; 2011 Dec; 4(12):1239-49. PubMed ID: 22172779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade.
    Kosmala W; Przewlocka-Kosmala M; Szczepanik-Osadnik H; Mysiak A; Marwick TH
    Heart; 2013 Mar; 99(5):320-6. PubMed ID: 23343682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated backscatter as a fibrosis marker in the metabolic syndrome: association with biochemical evidence of fibrosis and left ventricular dysfunction.
    Kosmala W; Przewlocka-Kosmala M; Wojnalowicz A; Mysiak A; Marwick TH
    Eur Heart J Cardiovasc Imaging; 2012 Jun; 13(6):459-67. PubMed ID: 22185752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy.
    Gupta A; Schiros CG; Gaddam KK; Aban I; Denney TS; Lloyd SG; Oparil S; Dell'Italia LJ; Calhoun DA; Gupta H
    J Hum Hypertens; 2015 Apr; 29(4):241-6. PubMed ID: 25231508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
    Udelson JE; Feldman AM; Greenberg B; Pitt B; Mukherjee R; Solomon HA; Konstam MA
    Circ Heart Fail; 2010 May; 3(3):347-53. PubMed ID: 20299607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker and imaging responses to spironolactone in subclinical diabetic cardiomyopathy.
    Jellis CL; Sacre JW; Wright J; Jenkins C; Haluska B; Jeffriess L; Martin J; Marwick TH
    Eur Heart J Cardiovasc Imaging; 2014 Jul; 15(7):776-86. PubMed ID: 24472731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the PPARGC1A Gly482Ser polymorphism on left ventricular structural and functional abnormalities in patients with hypertension.
    Rojek A; Cielecka-Prynda M; Przewlocka-Kosmala M; Laczmanski L; Mysiak A; Kosmala W
    J Hum Hypertens; 2014 Sep; 28(9):557-63. PubMed ID: 24718382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spironolactone improves diastolic function in the elderly.
    Roongsritong C; Sutthiwan P; Bradley J; Simoni J; Power S; Meyerrose GE
    Clin Cardiol; 2005 Oct; 28(10):484-7. PubMed ID: 16274097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and design of a randomized trial on the impact of aldosterone antagonism on cardiac structure and function in diabetic cardiomyopathy.
    Leung M; Wong VW; Heritier S; Mihailidou AS; Leung DY
    Cardiovasc Diabetol; 2013 Oct; 12():139. PubMed ID: 24083804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease.
    Edwards NC; Ferro CJ; Kirkwood H; Chue CD; Young AA; Stewart PM; Steeds RP; Townend JN
    Am J Cardiol; 2010 Nov; 106(10):1505-11. PubMed ID: 21059444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relation of circulating markers of fibrosis and progression of left and right ventricular dysfunction in hypertensive patients with heart failure.
    Plaksej R; Kosmala W; Frantz S; Herrmann S; Niemann M; Störk S; Wachter R; Angermann CE; Ertl G; Bijnens B; Weidemann F
    J Hypertens; 2009 Dec; 27(12):2483-91. PubMed ID: 19887955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum versus Imaging Biomarkers in Friedreich Ataxia to Indicate Left Ventricular Remodeling and Outcomes.
    Mehta N; Chacko P; Jin J; Tran T; Prior TW; He X; Agarwal G; Raman SV
    Tex Heart Inst J; 2016 Aug; 43(4):305-10. PubMed ID: 27547137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating levels of biomarkers of collagen synthesis and ventricular function and dyssynchrony in adolescents and young adults after repair of tetralogy of Fallot.
    Lai CT; Chan KW; Wong SJ; Chow PC; Cheung YF
    Am Heart J; 2011 Sep; 162(3):467-73. PubMed ID: 21884862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction.
    Hayashi M; Tsutamoto T; Wada A; Tsutsui T; Ishii C; Ohno K; Fujii M; Taniguchi A; Hamatani T; Nozato Y; Kataoka K; Morigami N; Ohnishi M; Kinoshita M; Horie M
    Circulation; 2003 May; 107(20):2559-65. PubMed ID: 12732605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldosterone blockade in metabolic syndrome: hitting the target or still missing some links?
    Leung DY
    JACC Cardiovasc Imaging; 2011 Dec; 4(12):1250-2. PubMed ID: 22172780
    [No Abstract]   [Full Text] [Related]  

  • 16. Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction.
    Fraccarollo D; Galuppo P; Schmidt I; Ertl G; Bauersachs J
    Cardiovasc Res; 2005 Jul; 67(1):97-105. PubMed ID: 15949473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial.
    Ravassa S; Trippel T; Bach D; Bachran D; González A; López B; Wachter R; Hasenfuss G; Delles C; Dominiczak AF; Pieske B; Díez J; Edelmann F
    Eur J Heart Fail; 2018 Sep; 20(9):1290-1299. PubMed ID: 29709099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study.
    Izawa H; Murohara T; Nagata K; Isobe S; Asano H; Amano T; Ichihara S; Kato T; Ohshima S; Murase Y; Iino S; Obata K; Noda A; Okumura K; Yokota M
    Circulation; 2005 Nov; 112(19):2940-5. PubMed ID: 16275882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of mineralocorticoid receptor antagonists on changes in cardiac structure and function of left ventricular dysfunction: a meta-analysis of randomized controlled trials.
    Li X; Qi Y; Li Y; Zhang S; Guo S; Chu S; Gao P; Zhu D; Wu Z; Lu L; Shen W; Jia N; Niu W
    Circ Heart Fail; 2013 Mar; 6(2):156-65. PubMed ID: 23400891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Left ventricular function impairment in patients with normal-weight obesity: contribution of abdominal fat deposition, profibrotic state, reduced insulin sensitivity, and proinflammatory activation.
    Kosmala W; Jedrzejuk D; Derzhko R; Przewlocka-Kosmala M; Mysiak A; Bednarek-Tupikowska G
    Circ Cardiovasc Imaging; 2012 May; 5(3):349-56. PubMed ID: 22407472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.